- Previous Close
41.80 - Open
41.60 - Bid 41.80 x --
- Ask 41.80 x --
- Day's Range
40.80 - 42.50 - 52 Week Range
40.80 - 102.50 - Volume
13,283 - Avg. Volume
3,201 - Market Cap (intraday)
194.907M - Beta (5Y Monthly) 0.58
- PE Ratio (TTM)
-- - EPS (TTM)
-7.50 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
121.13
Captor Therapeutics Spolka Akcyjna, a biopharmaceutical company, focuses on the discovery and development of protein degradation drugs for cancer and autoimmune diseases. The company provides Targeted Protein Degradation technology that overcomes many existing drug limitations by removing proteins resistant to available therapeutics. It has various therapeutic molecules in the preclinical stage. The company was incorporated in 2015 and is headquartered in Wroclaw, Poland.
www.captortherapeutics.comRecent News: CTX.WA
View MorePerformance Overview: CTX.WA
Trailing total returns as of 12/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CTX.WA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CTX.WA
View MoreValuation Measures
Market Cap
194.91M
Enterprise Value
151.61M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
11.06
Price/Book (mrq)
4.74
Enterprise Value/Revenue
7.83
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-250.46%
Return on Assets (ttm)
-38.23%
Return on Equity (ttm)
-87.91%
Revenue (ttm)
18.64M
Net Income Avi to Common (ttm)
-46.69M
Diluted EPS (ttm)
-7.50
Balance Sheet and Cash Flow
Total Cash (mrq)
56.52M
Total Debt/Equity (mrq)
12.53%
Levered Free Cash Flow (ttm)
-24.98M